138 results
8-K
EX-99.1
VIR
Vir Biotechnology Inc
18 Apr 24
Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy
8:44am
trials, including the enrollment of
Vir’s clinical trials, and the expected timing of data readouts and presentations; the potential benefits, safety
8-K
EX-99.1
VIR
Vir Biotechnology Inc
22 Feb 24
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
4:12pm
, and the expected timing of data readouts and presentations; the potential benefits, safety, and efficacy of Vir’s investigational therapies; and risks … and actual results, including uncertainty as to whether the anticipated benefits of the BARDA collaboration can be achieved; unexpected safety or efficacy
S-3ASR
EX-4.6
c6i3vkd cscqbu2z
3 Nov 23
Automatic shelf registration
4:33pm
S-3ASR
fz1u15jv
3 Nov 23
Automatic shelf registration
4:33pm
S-3ASR
EX-4.5
n5s1zi 7an3kfz1cd
3 Nov 23
Automatic shelf registration
4:33pm
S-3ASR
EX-1.2
o1vuvp
3 Nov 23
Automatic shelf registration
4:33pm
8-K
EX-99.1
ak852pvc
2 Nov 23
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
4:09pm
8-K
tuq7apfs3cvcgub xh4
3 Oct 23
Entry into a Material Definitive Agreement
8:01am
8-K
EX-99.1
m8f3fy
3 Aug 23
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
4:14pm
8-K
EX-99.1
uezfdv 4q
20 Jul 23
Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating
8:04am
8-K
ex9lm
20 Jul 23
Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating
8:04am